Header Logo

Connection

Arthur Krieg to Receptors, Cell Surface

This is a "connection" page, showing publications Arthur Krieg has written about Receptors, Cell Surface.
Connection Strength

2.000
  1. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec; 27(6):460-71.
    View in: PubMed
    Score: 0.196
  2. Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology. 2004 Oct; 113(2):212-23.
    View in: PubMed
    Score: 0.194
  3. Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, W?llner M, Wader T, Liu M, Kritzler A, Krieg AM. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. J Leukoc Biol. 2004 Sep; 76(3):585-93.
    View in: PubMed
    Score: 0.191
  4. Vollmer J, Rankin R, Hartmann H, Jurk M, Samulowitz U, Wader T, Janosch A, Schetter C, Krieg AM. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother. 2004 Jun; 48(6):2314-7.
    View in: PubMed
    Score: 0.190
  5. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep. 2004 Mar; 6(2):88-95.
    View in: PubMed
    Score: 0.187
  6. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004 Jan; 34(1):251-62.
    View in: PubMed
    Score: 0.185
  7. Krieg AM. CpG motifs: the active ingredient in bacterial extracts? Nat Med. 2003 Jul; 9(7):831-5.
    View in: PubMed
    Score: 0.178
  8. Krieg AM. A role for Toll in autoimmunity. Nat Immunol. 2002 May; 3(5):423-4.
    View in: PubMed
    Score: 0.164
  9. Krieg AM. Now I know my CpGs. Trends Microbiol. 2001 Jun; 9(6):249-52.
    View in: PubMed
    Score: 0.154
  10. Edwards L, Williams AE, Krieg AM, Rae AJ, Snelgrove RJ, Hussell T. Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur J Immunol. 2005 Jan; 35(1):273-81.
    View in: PubMed
    Score: 0.049
  11. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res. 2005 Jan 01; 11(1):361-9.
    View in: PubMed
    Score: 0.049
  12. Pichyangkul S, Yongvanitchit K, Kum-arb U, Hemmi H, Akira S, Krieg AM, Heppner DG, Stewart VA, Hasegawa H, Looareesuwan S, Shanks GD, Miller RS. Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. J Immunol. 2004 Apr 15; 172(8):4926-33.
    View in: PubMed
    Score: 0.047
  13. Vollmer J, Jurk M, Samulowitz U, Lipford G, Forsbach A, W?llner M, Tluk S, Hartmann H, Kritzler A, M?ller C, Schetter C, Krieg AM. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J Endotoxin Res. 2004; 10(6):431-8.
    View in: PubMed
    Score: 0.046
  14. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol. 2002 Jun; 3(6):499.
    View in: PubMed
    Score: 0.041
  15. Krieg AM. From A to Z on CpG. Trends Immunol. 2002 Feb; 23(2):64-5.
    View in: PubMed
    Score: 0.040
  16. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct; 31(10):3026-37.
    View in: PubMed
    Score: 0.039
  17. Abel K, Wang Y, Fritts L, Sanchez E, Chung E, Fitzgerald-Bocarsly P, Krieg AM, Miller CJ. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin Diagn Lab Immunol. 2005 May; 12(5):606-21.
    View in: PubMed
    Score: 0.013
  18. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov; 24(6):693-701.
    View in: PubMed
    Score: 0.012
  19. Marshak-Rothstein A, Busconi L, Lau CM, Tabor AS, Leadbetter EA, Akira S, Krieg AM, Lipford GB, Viglianti GA, Rifkin IR. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. J Endotoxin Res. 2004; 10(4):247-51.
    View in: PubMed
    Score: 0.012
  20. Jurk M, Schulte B, Kritzler A, Noll B, Uhlmann E, Wader T, Schetter C, Krieg AM, Vollmer J. C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology. 2004; 209(1-2):141-54.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.